Mintz Levin congratulates its client Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), for receiving approval from the U.S. Food and Drug Administration (FDA) for INCIVEK™ (telaprevir) tablets for treatment of persons with genotype 1 chronic hepatitis C.